Item 7.01 Regulation FD.

On June 9, 2022, Blueprint Medicines Corporation (the "Company") is presenting updates on the AYVAKIT/AYVAKYT (avapritinib) development program in systemic mastocytosis and other business updates at the 2022 Jefferies Healthcare Conference. A copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.




Item 8.01 Other Events.

On June 9, 2022, the Company issued a press release announcing data from the AYVAKIT/AYVAKYT (avapritinib) development program from various presentations at the European Hematology Association 2022 Congress. A copy of the press release is filed herewith as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.



Exhibit No.                                  Description
  99.1           Corporate slide presentation of Blueprint Medicines Corporation dated
               June 9, 2022
  99.2           Press release issued by Blueprint Medicines Corporation on June 9,
               2022
104            Cover Page Interactive Data File (embedded within the Inline XBRL
               document and incorporated as Exhibit 101)

© Edgar Online, source Glimpses